Marizyme, Inc. (MRZM)
Key Executives
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. David L. Barthel M.B.A. | CEO, Secretary & Director | 350k | -- | 1958 |
Mr. George Kovalyov C.A., CPA | CFO, Treasurer & Director | 168k | -- | 1985 |
Dr. Catherine J. Pachuk Ph.D. | Executive VP & Chief Scientific Officer | 325k | -- | 1957 |
Dr. Claudio Rigatto M.D. | Chief Medical Officer of My Health Logic | -- | -- | -- |
Kari Jacobson | Controller | -- | -- | -- |
Mr. Harrison Albert Ross C.F.A. | Vice President of Finance | -- | -- | 1993 |
Marizyme, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
Description
Marizyme, Inc., a multi-technology biomedical company, develops and commercializes medical technologies to enhances patients health. It's product portfolio includes DuraGraft, a single-use intraoperative vascular graft treatment that protects against ischemic injury and reduces the incidence and complications of graft failure; MATLOC, a point-of-care, lab-on-chip digital screening and diagnostic device platform, developed for quantitative chronic kidney disease assessment; and Krillase, a protein enzyme that provides a therapeutics opportunity for wound healing, thrombosis, and pet health. The company also engages in the development of MAR-FG-001, a fat grafting technology for the use during fat grafting procedures. Marizyme, Inc. was formerly known as GBS Enterprises Incorporated and changed its name to Marizyme, Inc. in March 2018. The company was incorporated in 2007 and is based in Jupiter, Florida.
Corporate Governance
Upcoming Events
June 3, 2024 at 8:00 PM UTC - June 18, 2024 at 8:00 PM UTC
Marizyme, Inc. Earnings Date
Recent Events
October 13, 2023 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission